BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34605020)

  • 1. Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study.
    Nerich V; Guyeux C; Henry-Amar M; Couturier R; Thieblemont C; Ribrag V; Tilly H; Haioun C; Casasnovas RO; Morschhauser F; Feugier P; Sibon D; Ysebaert L; Nicolas-Virelizier E; Broussais-Guillaumot F; Damaj GL; Jais JP; Salles G; Woronoff-Lemsi M; Mounier N
    Cancer; 2022 Feb; 128(3):519-528. PubMed ID: 34605020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional study.
    Mounier N; Anthony S; Busson R; Thieblemont C; Ribrag V; Tilly H; Haioun C; Casasnovas RO; Morschhauser F; Feugier P; Delarue R; Ysebaert L; Sebban C; Broussais-Guillaumot F; Damaj G; Nerich V; Jais JP; Laborde L; Salles G; Henry-Amar M
    Cancer; 2019 Jul; 125(13):2291-2299. PubMed ID: 30901086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995.
    Freeman M; Vose J; Bennett C; Anderson J; Kessinger A; Turner K; Pierson J; Bishop M; Bierman P; Armitage J
    Bone Marrow Transplant; 1999 Sep; 24(6):679-84. PubMed ID: 10490736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
    J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study.
    Majhail NS; Ness KK; Burns LJ; Sun CL; Carter A; Francisco L; Forman SJ; Bhatia S; Baker KS
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1153-9. PubMed ID: 17889351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semen quality in non-Hodgkin lymphoma survivors: a monocentric retrospective study.
    Pallotti F; Pelloni M; Faja F; Di Chiano S; Di Rocco A; Lenzi A; Lombardo F; Paoli D
    Hum Reprod; 2021 Jan; 36(1):16-25. PubMed ID: 33257989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment.
    Kutikova L; Bowman L; Chang S; Long SR; Arning M; Crown WH
    Leuk Lymphoma; 2006 Aug; 47(8):1535-44. PubMed ID: 16966264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost analysis of autologous peripheral stem cell transplantation versus autologous bone marrow transplantation for patients with non Hodgkin's lymphoma and acute lymphoblastic leukaemia.
    Jerjis S; Croockewit S; Muus P; Schaap N; Preijers F; de Witte T
    Leuk Lymphoma; 1999 Dec; 36(1-2):33-43. PubMed ID: 10613448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
    Chen YB; Batchelor T; Li S; Hochberg E; Brezina M; Jones S; Del Rio C; Curtis M; Ballen KK; Barnes J; Chi AS; Dietrich J; Driscoll J; Gertsner ER; Hochberg F; LaCasce AS; McAfee SL; Spitzer TR; Nayak L; Armand P
    Cancer; 2015 Jan; 121(2):226-33. PubMed ID: 25204639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.
    van Agthoven M; Kramer MH; Sonneveld P; van der Hem KG; Huijgens PC; Wijermans PW; Kluin-Nelemans HC; Schaafsma MR; Biesma DH; Mattijssen V; Uyl-de Groot CA; Hagenbeek A
    Haematologica; 2005 Oct; 90(10):1422-32. PubMed ID: 16219580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France.
    MouniƩ M; Costa N; Conte C; Petiot D; Fabre D; Despas F; Lapeyre-Mestre M; Laurent G; Savy N; Molinier L
    J Med Econ; 2020 Mar; 23(3):235-242. PubMed ID: 31876205
    [No Abstract]   [Full Text] [Related]  

  • 12. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991.
    Bennett CL; Armitage JL; Armitage GO; Vose JM; Bierman PJ; Armitage JO; Anderson JR
    J Clin Oncol; 1995 Apr; 13(4):969-73. PubMed ID: 7707125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
    Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
    Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment].
    Anthony S; Hebel P; Garrel A; Oliveri V; Thieblemont C; Ribrag V; Tilly H; Haioun C; Casasnovas RO; Morschhauser F; Feugier P; Delarue R; Ysebaert L; Sebban C; Broussais F; Damaj G; Nerich V; Jais JP; Salles G; Henry-Amar M; Mounier N
    Bull Cancer; 2017 Mar; 104(3):221-231. PubMed ID: 28214006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic stem cell transplantation for non-Hodgkin lymphoma.
    Bhatt VR; Vose JM
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1073-95. PubMed ID: 25459180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma.
    Majhail NS; Bajorunaite R; Lazarus HM; Wang Z; Klein JP; Zhang MJ; Rizzo JD
    Br J Haematol; 2009 Oct; 147(1):129-39. PubMed ID: 19573079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The forgotten survivor: A comprehensive review on Non-Hodgkin lymphoma survivorship.
    Alabdaljabar MS; Durani U; Thompson CA; Constine LS; Hashmi SK
    Am J Hematol; 2022 Dec; 97(12):1627-1637. PubMed ID: 36069675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic assessment in the management of non-Hodgkin's lymphoma.
    van Agthoven M; Uyl-de Groot CA; Sonneveld P; Hagenbeek A
    Expert Opin Pharmacother; 2004 Dec; 5(12):2529-48. PubMed ID: 15571470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of oncologists and primary care physicians in providing follow-up care to non-Hodgkin lymphoma survivors within 5 years of diagnosis: a population-based study.
    Forsythe LP; Arora NK; Alfano CM; Weaver KE; Hamilton AS; Aziz N; Rowland JH
    Support Care Cancer; 2014 Jun; 22(6):1509-17. PubMed ID: 24414999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial.
    van Agthoven M; Vellenga E; Fibbe WE; Kingma T; Uyl-de Groot CA
    Eur J Cancer; 2001 Sep; 37(14):1781-9. PubMed ID: 11549432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.